| Date |
Subject |
Media |
| 2025-08-06 |
Breakthrough in Pulmonary Hypertension Diagnosis: Results in 10 Minutes
|
Pulmonary hypertension is a highly fatal cardiopulmonary disease that often suffers from delayed diagnosis due to subtle early symptoms, increasing patient mortality risk. Taipei Veterans General Hospital recently announced a major research breakthrough, completing the world’s first multinational and multicenter validation of an "ECG-Based Pulmonary Hypertension Detection System." This system can automatically analyze electrocardiograms within 10 minutes and instantly transmit positive high-risk patient results to clinicians, assisting in timely scheduling of further examinations such as echocardiography, thereby improving survival rates. |
| 2025-08-06 |
Bora Pharmaceuticals Reports H1 Revenue Surpassing NT$10 Billion, Up 26.9%, Setting Historical Record
|
Bora Pharmaceuticals announced on the 10th that its preliminary consolidated revenue for June reached NT$1.65 billion, a 2.7% decrease compared to the same period last year. When measured in U.S. dollars, however, June revenue grew 10.3% from May and increased 3.4% year-over-year. The main factor for this discrepancy was the appreciation of the New Taiwan dollar. For the first half of this year, Bora’s cumulative revenue exceeded NT$10 billion, representing a 26.9% year-on-year increase and setting a new historical record for the period. Overall operations continue to show steady growth. |
| 2025-08-06 |
Gongwin Biopharm’s U.S. Subsidiary to Receive $50 Million Investment from Fund A for Clinical Trials in the U.S.
|
Gongwin-KY announced on the evening of July 10 that its subsidiary, Gongwin Biopharm, received a letter of intent (LOI) from Fund A on July 9. Fund A plans to participate in the establishment of Gongwin’s U.S. subsidiary and intends to invest up to $50 million USD (approximately NT$1.462 billion), representing about half of the Series A fundraising target of $100 million USD. This round of fundraising is expected to release approximately 20% to 25% of the equity. |
| 2025-08-06 |
Daiken Biomedical’s June Revenue Soars Over 90% Year-on-Year with Seven Strategic Engines for Expansion
|
Daiken Biomedical announced that its consolidated revenue for June reached NT$175 million, a 93.35% increase compared to the same period last year. The company’s cumulative revenue from January to June grew 50.57% year-on-year. Concurrently, Daiken unveiled its “Seven Strategic Engines” international expansion blueprint, aiming to establish itself as Asia’s most promising health technology brand. |
| 2025-08-06 |
SYNMOSA Reports 5.7 Billion NTD Consolidated Revenue in June, Up 51.5% Year-on-Year
|
SYNMOSA saw its consolidated revenue reach 575 million NTD in June, representing a 51.5% increase compared to the same period last year and an 8% rise from May. The accumulated consolidated revenue for the first half of the year totaled 3.062 billion NTD, up 16.9% year-on-year. |
| 2025-08-06 |
Import Drug Tariffs at 200% Prompt Bora Pharmaceuticals and Lotus Pharmaceutical to Boost U.S. Manufacturing
|
U.S. President Donald Trump announced plans to impose a 200% tariff on imported drugs, allowing the industry a one-year grace period to relocate production lines to the United States. In response, Taiwan’s two major export-focused pharmaceutical companies, Bora Pharmaceuticals and Lotus Pharmaceutical, recently confirmed they have increased the proportion of drug production on their U.S. manufacturing lines. |
| 2025-08-06 |
Ever Fortune’s Hair Growth Cap Receives TFDA Medical Device Certification, Targets Hair Loss Treatment Market
|
Ever Fortune announced on the 9th that its subsidiary, Ever Wynn Technology, jointly developed the Reness Hair Growth Cap, which has received medical device certification from Taiwan’s TFDA. The company plans to apply next for U.S. FDA approval, aiming to enter the international market with its hair growth technology. |
| 2025-08-06 |
TaiHao Medical Inc. Launches AI Medical Devices in Southeast Asia
|
Taiwanese AI medical imaging leader TaiHao Medical Inc. announced multiple major international developments on July 10, demonstrating its technological strength and commercial progress in the global healthcare market. |
| 2025-08-06 |
Foresee Pharmaceuticals Reports June Revenue of NT$38.86 Million, Up 179% Month-on-Month; H1 Revenue Reaches NT$222 Million, Growing 12% Year-on-Year
|
Foresee Pharmaceuticals announced on the 9th that its consolidated revenue for June was approximately NT$38.86 million, representing a 179% increase from May and a 22% rise year-on-year. The cumulative consolidated revenue for the first half of this year reached about NT$222 million, marking a 12% year-on-year growth. |
| 2025-07-29 |
Tanvex’s June Consolidated Revenue Soars 997% Year-on-Year, Setting New Record; CDMO Revenue Surges
|
Tanvex-KY announced on the 8th that its preliminary consolidated revenue for June reached NT$26.56 million, up approximately 127% from the previous month and soaring 997.56% year-on-year, marking consecutive monthly growth and a new record for the same period. The preliminary consolidated revenue for Q2 totaled NT$46.82 million. Although exchange rate fluctuations caused a slight 6% decrease in NT dollar terms compared to the previous quarter, when measured in functional currency USD, Tanvex Biotech’s Q2 revenue reached about US$1.56 million, representing a 3% increase quarter-on-quarter. |
